Definitive Contract 75N93018C00039
Award Date
8/9/18
Potential Completion Date
8/14/23
Potential Value
$3.6M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Via Therapeutics, LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Austin, TX 78750, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $299,995 firm fixed-price contract to Via Therapeutics, LLC, a small business located in Austin, Texas. The contract is for the development of low-cost, shelf-stable, patient-adaptable clofazimine mini-tablets to treat tuberculosis in pediatric patients. This contract supports Via Therapeutics' pharmaceutical research and development efforts related to...
The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
This is a $1,486,937 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of an inhaled drug combination for tuberculosis therapy under the SBIR Phase II program. Key tasks include the manufacture of spray-dried combination drugs, technical support for pharmacokinetic and...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $220,582 Small Business Innovation Research (SBIR) Phase I contract to Oak Therapeutics Inc., a pharmaceutical company based in Westlake Village, California. The contract is for the development of oral dissolving strips for the delivery of isoniazid, a medication used to treat tuberculosis, in children and adults. This contract is a Firm Fixed Price definitive...
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to the University of Texas Medical Branch at Galveston (UTMB). The $788,445.00 cost-plus-fixed-fee contract supports testing of a novel inhaled clofazimine (CFZ) dry powder formulation in a mouse model of Mycobacterium tuberculosis. This work is being conducted under UTMB's existing $146.3 million Indefinite Delivery...
This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to The Global Alliance For TB Drug Development Inc., a non-profit organization. The $9,851,406.00 cost-no-fee contract is for the development of a novel modulator targeting proteostasis for the treatment of M. tuberculosis, with a completion date of April 30, 2028. The contract was awarded under NIAID's Broad...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase II contract to Luna Innovations Incorporated, a manufacturer of goods, for the development of "Innovative Oral Formulations for Anti-TB Drugs". The firm-fixed-price contract, with a potential value of $1,499,796.00, was awarded on August 28, 2018, and is set to be completed by November 30, 2020. As a...
This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....
The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH NIAID) awarded a $21,640,423 cost-plus-fixed-fee definitive contract to Versatope Therapeutics Inc., a for-profit biotechnology company located in Lowell, Massachusetts. The contract was awarded in September 2019 under the Broad Agency Announcement 2018 (BAA2018) program to advance the development of recombinant outer membrane vesicle-based vaccines for infectious diseases such as malaria. The contract...